Tempus announces three abstracts accepted for presentation at the European Society for Medical Oncology Congress 2022

September 9, 2022 10:32 a.m. EDT

Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.

CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that three abstracts have been accepted for presentation at the European Society for Medical Oncology Congress 2022 ( ESMO), which will be held in Paris, France, from September 9-13, 2022. Tempus presents the three abstracts, including an oral presentation and two poster presentations.

“As we continue to develop our comprehensive precision oncology solutions for clinical use in Europe, we are excited to showcase the research for the first time at ESMO this year,” said James L. Chen, MD, senior vice president of cancer informatics at Tempus. “This year’s abstracts showcase Tempus’ deep molecular profiling capabilities, including our use of AI-based diagnostic tests, to inform data-driven patient care.”

This year, Tempus will share some of its latest scientific and clinical research results through oral discussions and poster presentations, including:

  • Poster presentation (923P): Molecular Classification of Unknown Primary Cancers Expands and Refines Treatment Options
    • Session date and time: September 11, 2022
    • Location: Space Posters, Hall 4, Paris Expo Porte de Versailles
    • Insight: In this retrospective study, Tempus’ AI-based algorithmic test of tumor origin (TO) – which uses tumor RNA expression results to predict the type of patient’s most likely cancer from 68 possible diagnoses – provided significant data that would have affected doctors. therapeutic decision-making for patients with cancer of unknown primary (CUP). In a study of 289 patients, 81% of patients with CUP would have their treatment informed by TO tumor classification, ultimately expanding treatment options for patients with CUP.
  • Oral discussion (1529MB): The genomic landscape of small cell lung cancer in patients who never smoke
    • Session date and time: September 12, 2022
    • Location: 7.3.O, Orleans Auditorium, Paris Expo Porte de Versailles
    • Insight: Tempus conducted a retrospective analysis of anonymized records of patients with small cell lung cancer who self-reported as never smokers or “smokers/ex-smokers” and who underwent full genomic profiling with the Tempus xT test. It was determined that “never smokers” patients were more likely to harbor mutations in oncogenic factors (e.g., EGFR and PIK3CA) and had lower tumor mutational load (TMB) and immune cell infiltration than patients. “current/ex-smoker” patients. Ultimately, this study found that the genomic landscape of non-smokers with small cell lung cancer differs significantly from that of smokers with small cell lung cancer.
  • Poster Presentation (1107P): BRAF Mutations and Fusions in a Real-Life Cohort of Non-Small Cell Lung Cancer Patients
    • Session date and time: September 12, 2022
    • Location: Space Posters, Hall 4, Paris Expo Porte de Versailles
    • Insight: Tempus Retrospectively Analyzed Anonymized Records of 6,511 Non-Small Cell Lung Cancer (NSCLC) Patients Who Underwent Full Genomic Profiling with the Tempus xT Test for Class I/II/III/Other BRAF Mutations /unclassified. This study found that the prevalence of specific biomarkers varied by BRAF mutation class, including EGFR, KRAS, and NF1, ultimately determining that the genomic profiles of patients with BRAF alterations are distinct by variant class.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data and an operating system to make that data accessible and useful, Tempus enables physicians to make decisions based on near real-time data to deliver personalized care. to patients and, in parallel, facilitates the discovery, development and delivery of optimal treatments. The goal is for each patient to benefit from the treatment of others that have gone before them by providing doctors with tools that learn as the company collects more data. For more information, visit tempus.com.

Erin Caron

Senior Director of Communications

[email protected]

Source: Tempus

Serious news for serious traders! Try StreetInsider.com Premium for free!

You may also be interested in

Comments are closed.